The fibrinolysis inhibitor α₂-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer

References

• Achen MG, Gad JM, Stacker SA, Wilks AF. 1997. Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors 15:69–80.
   PubMed Web of Science ®Google Scholar
• Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548–553.
   PubMed Web of Science ®Google Scholar
• Achen MG, Mann GB, Stacker SA. 2006. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 94:1355–1360.
   PubMed Web of Science ®Google Scholar
• Achen MG, McColl BK, Stacker SA. 2005. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7:121–127.
   PubMed Web of Science ®Google Scholar
• Achen MG, Roufail S, Domagala T, Catimel B, Nice EC, Geleick DM, Murphy R, Scott AM, Caesar C, Makinen T, Alitalo K, Stacker SA. 2000. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur J Biochem 267:2505–2515.
   PubMedGoogle Scholar
• Achen MG, Stacker SA. 2012. Vascular endothelial growth factor-D: signalling mechanisms, biology and clinical relevance. Growth Factors 30:283–296.
   PubMed Web of Science ®Google Scholar
• Alitalo K. 2011. The lymphatic vasculature in disease. Nat Med 17:1371–1380.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG. 2001. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J Biol Chem 276:44307–44314.
   PubMed Web of Science ®Google Scholar
• Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. 1999. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144:789–801.
   PubMed Web of Science ®Google Scholar
• Basak A, Khatib AM, Mohottalage D, Basak S, Kolajova M, Bag SS, Basak A. 2009. A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C. PLoS One 4:e7700.
   PubMed Web of Science ®Google Scholar
• Bui HM, Enis D, Robciuc MR, Nurmi HJ, Cohen J, Chen M, Yang Y, et al. 2016. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. J Clin Invest 126:2167–2180.
   PubMed Web of Science ®Google Scholar
• Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, et al. 2002. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99:4434–4442.
   PubMed Web of Science ®Google Scholar
• Carpenter SL, Mathew P. 2008. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 14:1250–1254.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404.
   PubMed Web of Science ®Google Scholar
• Dadras SS, Paul T, Bertoncini PT, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, et al. 2003. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162:1951–1960.
   PubMed Web of Science ®Google Scholar
• Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, et al. 2016. Differential receptor binding and regulatory mechanisms for the lymphangiogenic growth factors vascular endothelial growth factor (VEGF)-C and -D. J Biol Chem 291:27265–27278.
   PubMed Web of Science ®Google Scholar
• Davydova N, Roufail S, Streltsov VA, Stacker SA, Achen MG. 2011. The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding. J Mol Biol 407:581–593.
   PubMed Web of Science ®Google Scholar
• Davydova N, Streltsov VA, Roufail S, Lovrecz GO, Stacker SA, Adams TE, Achen MG. 2012. Preparation of human vascular endothelial growth factor-D for structural and preclinical therapeutic studies. Protein Expr Purif 82:232–239.
   PubMed Web of Science ®Google Scholar
• Doucet A, Overall CM. 2008. Protease proteomics: revealing protease in vivo functions using systems biology approaches. Mol Aspects Med 29:339–358.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1.
   PubMed Web of Science ®Google Scholar
• Harris NC, Davydova N, Roufail S, Paquet-Fifield S, Paavonen K, Karnezis T, Zhang YF, et al. 2013. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem 288:8176–8186.
   PubMed Web of Science ®Google Scholar
• Harris NC, Paavonen K, Davydova N, Roufail S, Sato T, Zhang YF, Karnezis T, et al. 2011. Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer. FASEB J 25:2615–2625.
   PubMed Web of Science ®Google Scholar
• Hayashido Y, Hamana T, Ishida Y, Shintani T, Koizumi K, Okamoto T. 2007. Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. Oncol Rep 17:417–423.
   PubMed Web of Science ®Google Scholar
• He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:819–825.
   PubMed Web of Science ®Google Scholar
• He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, et al. 2005. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739–4746.
   PubMed Web of Science ®Google Scholar
• Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, Wedge SR, et al. 2008. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68:4754–4762.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. 2013. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 108:766–770.
   PubMed Web of Science ®Google Scholar
• Heissig B, Eiamboonsert S, Salama Y, Shimazu H, Dhahri D, Munakata S, Tashiro Y, Hattori K. 2016. Cancer therapy targeting the fibrinolytic system. Adv Drug Deliv Rev 99:172–179.
   PubMed Web of Science ®Google Scholar
• Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. 2016. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol 7:621.
   PubMed Web of Science ®Google Scholar
• Jain RK, Padera TP. 2002. Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy. J Natl Cancer Inst 94:785–787.
   PubMedGoogle Scholar
• Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppanen VM, Holopainen T, Kivela R, et al. 2014. CCBE1 enhances lymphangiogenesis via a disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. Circulation 129:1962–1971.
   PubMed Web of Science ®Google Scholar
• Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898–3911.
   PubMed Web of Science ®Google Scholar
• Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, et al. 2012. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21:181–195.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786–1790.
   PubMed Web of Science ®Google Scholar
• Khatib AM, Lahlil R, Scamuffa N, Akimenko MA, Ernest S, Lomri A, Lalou C, et al. 2010. Zebrafish proVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed proVEGF-C during fin regeneration. PLoS One 5:10.
   Web of Science ®Google Scholar
• Kwaan HC, McMahon B. 2009. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148:43–66.
   PubMedGoogle Scholar
• Law RH, Sofian T, Kan WT, Horvath AJ, Hitchen CR, Langendorf CG, Buckle AM, et al. 2008. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 111:2049–2052.
   PubMed Web of Science ®Google Scholar
• Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, et al. 2005. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901–6909.
   PubMed Web of Science ®Google Scholar
• Longstaff C, Kolev K. 2015. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 13 Suppl 1:S98–S105.
   PubMed Web of Science ®Google Scholar
• Lu BG, Sofian T, Law RH, Coughlin PB, Horvath AJ. 2011. Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition. J Biol Chem 286:24544–24552.
   PubMed Web of Science ®Google Scholar
• Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, et al. 2012. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1:191–199.
   PubMed Web of Science ®Google Scholar
• Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, et al. 2016. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest 126:3389–3402.
   PubMed Web of Science ®Google Scholar
• Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA. 2005. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19:397–410.
   PubMed Web of Science ®Google Scholar
• Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, et al. 2001. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762–4773.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, et al. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672–682.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Roufail S, Inder R, Caesar C, Karnezis T, Shayan R, Farnsworth RH, et al. 2013. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis 30:819–832.
   PubMed Web of Science ®Google Scholar
• McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, Alitalo K, et al. 2003. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198:863–868.
   PubMed Web of Science ®Google Scholar
• McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, et al. 2007. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 21:1088–1098.
   PubMed Web of Science ®Google Scholar
• Mekkawy AH, Morris DL, Pourgholami MH. 2009. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 5:1487–1499.
   PubMed Web of Science ®Google Scholar
• Mekkawy AH, Pourgholami MH, Morris DL. 2014. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med Res Rev 34:918–956.
   PubMed Web of Science ®Google Scholar
• Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. 2000. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156:1499–1504.
   PubMed Web of Science ®Google Scholar
• Paquet-Fifield S, Levy SM, Sato T, Shayan R, Karnezis T, Davydova N, Nowell CJ, et al. 2013. Vascular endothelial growth factor-d modulates caliber and function of initial lymphatics in the dermis. J Invest Dermatol 133:2074–2084.
   PubMed Web of Science ®Google Scholar
• Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, et al. 2005. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97:14–21.
   PubMedGoogle Scholar
• Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, et al. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92:1098–1106.
   PubMed Web of Science ®Google Scholar
• Rogers LD, Overall CM. 2013. Proteolytic post-translational modification of proteins: proteomic tools and methodology. Mol Cell Proteomics 12:3532–3542.
   PubMed Web of Science ®Google Scholar
• Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, et al. 2016. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemother Pharmacol 78:815–824.
   PubMed Web of Science ®Google Scholar
• Sato T, Paquet-Fifield S, Harris NC, Roufail S, Turner DJ, Yuan Y, Zhang YF, et al. 2016. VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. J Pathol 239:152–161.
   PubMed Web of Science ®Google Scholar
• Schaller J, Gerber SS. 2011. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 68:785–801.
   PubMed Web of Science ®Google Scholar
• Shayan R, Inder R, Karnezis T, Caesar C, Paavonen K, Ashton MW, Mann GB, et al. 2013. Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis. Clin Exp Metastasis 30:345–356.
   PubMed Web of Science ®Google Scholar
• Shayan R, Karnezis T, Murali R, Wilmott JS, Ashton MW, Taylor GI, Thompson JF, et al. 2012. Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology 61:702–710.
   PubMed Web of Science ®Google Scholar
• Shimamura K, Nakatani T, Ueda A, Sugama J, Okuwa M. 2009. Relationship between lymphangiogenesis and exudates during the wound-healing process of mouse skin full-thickness wound. Wound Repair Regen 17:598–605.
   PubMed Web of Science ®Google Scholar
• Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, Khatib AM. 2003. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111:1723–1732.
   PubMed Web of Science ®Google Scholar
• Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–198.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Baldwin ME, Achen MG. 2002. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16:922–934.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, et al. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186–191.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, et al. 1999. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274:32127–32136.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Williams RA, Achen MG. 2004. Lymphangiogenic growth factors as markers of tumor metastasis. Apmis 112:539–549.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. 2014. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14:159–172.
   PubMed Web of Science ®Google Scholar
• Swartz MA. 2014. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res 2:701–707.
   PubMed Web of Science ®Google Scholar
• Swedberg JE, Harris JM. 2012. Natural and engineered plasmin inhibitors: applications and design strategies. Chembiochem 13:336–348.
   PubMed Web of Science ®Google Scholar
• Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A. 2012. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost 10:2555–2562.
   PubMed Web of Science ®Google Scholar
• Wise LM, Ueda N, Dryden NH, Fleming SB, Caesar C, Roufail S, Achen MG, et al. 2003. Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens. J Biol Chem 278:38004–38014.
   PubMed Web of Science ®Google Scholar